Notice Number: NOT-DK-20-005

Key Dates
Release Date: October 17, 2019

Issued by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Purpose

This notice is to inform potential applicants that NIDDK is adding instructions for applications within section IV.2, Application and Submission Information for the PHS 398 Research Plan, Letters of Support section of RFA-DK-17-018, "Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R21 - Clinical Trial Optional)."

Section IV.2, Content and Form of Application Submission, PHS 398 Research Plan, Letters of Support

Current:

Letters of Support: Applications to this FOA must include a letter from the Chair or Vice-Chair of the Steering Committee of the IBDGC indicating that the IBDGC is willing to provide the ancillary study investigators with access to participants, samples and data, as needed.

Modified to read:

Letters of Support: Applications to this FOA must include a letter from the Chair or Vice-Chair of the Steering Committee of the IBDGC indicating that the IBDGC is willing to provide the ancillary study investigators with access to participants, samples and data, as needed. All requests for letters of support must be received in final form by COB December 4, 2019. For instructions on requesting a letter of support, please contact:

Ksenija Sabic,MPhil
Institute for Personalized Medicine
Icahn School of Medicine at Mount Sinai
Telephone: 212-824-9080
Email: ksenija.sabic@mssm.edu

All other aspects of the Funding Opportunity Announcement remain the same.

Inquiries

Please direct all inquiries to:

Robert W. Karp, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-451-8875
Email: karpr@mail.nih.gov